Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alectos OGA inhibitor
- Development stage
- Preclinical
- Lead developer
- Alectos Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Alectos Therapeutics is developing novel small-molecule O-GlcNAcase (OGA) inhibitors as disease-modifying therapies for neurodegenerative and acute neurological diseases. The program targets the OGA enzyme; inhibition of OGA leads to increased protein O-GlcNAcylation, which helps prevent the pathogenic aggregation of proteins such as tau, alpha-synuclein, TDP-43, and amyloid-beta, while also providing neuroprotection during cellular stress. While a previous candidate, MK-8719, was developed in partnership with Merck and reached Phase 1, Alectos has since repatriated the program and is currently advancing new, optimized OGA development candidates in the preclinical stage. The program is being evaluated for Alzheimer's disease, Parkinson's disease, acute ischemic stroke, and traumatic brain injury, and includes an OGA PET ligand to measure brain target engagement.
- Other names
- O-GlcNAcase inhibitor
02
Targets
OGA (Protein O-GlcNAcase)
Beyond the preview
Go deeper on Alectos OGA inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alectos OGA inhibitor.